Request Demo
Last update 08 May 2025
QLP2117
Last update 08 May 2025
Overview
Basic Info
Drug Type Antibody |
Synonyms |
Target |
Action modulators |
Mechanism CCR8 modulators(C-C motif chemokine receptor 8 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with QLP2117NCT06911827
A Phase Ib/II Open-Label, Dose-Escalation and Dose-expansion Clinical Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
NCT05830045
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients
CTR20231243
评估QLP2117治疗晚期实体瘤患者的安全性、耐受性、药代动力学、免疫原性和有效性的开放、多中心I期临床研究
[Translation] An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy of QLP2117 in patients with advanced solid tumors
100 Clinical Results associated with QLP2117
Login to view more data
100 Translational Medicine associated with QLP2117
Login to view more data
100 Patents (Medical) associated with QLP2117
Login to view more data
100 Deals associated with QLP2117
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 2 | China | 07 Apr 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | - | 01 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05830045 (SITC2024) Manual  | Phase 1 | 18 | QLP2117 (3 mg、10 mg、30 mg、90 mg、270 mg、540 mg、800 mg、1200 mg) | (caedzlxyiy) = not reached xzkimopios (ricveqepje ) | Positive | 05 Nov 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free